BC1618 是一种具有口服活性的 Fbxo48 抑制化合物，可刺激 AMPK 依赖性信号传导。它促进线粒体分裂，促进自噬并提高肝脏胰岛素敏感性。

BC1618 is an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling. It promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity.

BC1618, whose potency in stimulating Ampk-dependent signaling greatly exceeds 5-aminoimidazole-4-carboxamide-1-β-ribofuranoside (AICAR) or metformin.?This compound increases the biological activity of Ampk not by stimulating the activation of Ampk, but rather by preventing activated pAmpkα from Fbxo48-mediated degradation.?Consistenting with augmenting Ampk activity, BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity in high-fat-diet-induced obese mice[1].

2222094-18-8

C24H24F3NO2

415.456

2-Propanol, 1-[bis(phenylmethyl)amino]-3-[4-(trifluoromethyl)phenoxy]-

DMSO:100 mg/mL (240.70 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years